B

Blueprint Medicines Corp
D

BPMC

101.510
USD
1.13
(1.13%)
مغلق
حجم التداول
14,508
الربح لكل سهم
-1
العائد الربحي
-
P/E
-40
حجم السوق
6,555,735,366
أصول ذات صلة
ABBV
ABBV
0.810
(0.44%)
183.260 USD
AZN
AZN
-0.110
(-0.16%)
70.410 USD
BMY
BMY
-0.140
(-0.30%)
46.870 USD
GSK
GSK
-0.560
(-1.43%)
38.690 USD
JNJ
JNJ
0.360
(0.24%)
152.930 USD
LLY
LLY
-7.85
(-1.09%)
713.61 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
NVS
NVS
0.240
(0.21%)
112.750 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
المزيد
الأخبار المقالات

العنوان: Blueprint Medicines Corp

القطاع: Healthcare
الصناعة: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.